Funding profile · mRNA biomanufacturing

Sensible Biotechnologies

Two Form D notices, three and a half years apart, covering $15.35 million sold. The announcements in between describe more capital than the filings do.

$13.5MSold of $15.0M offered, Form D filed Sep 2, 2026
$15.35MTotal sold across both Form D notices since 2021
15Investors in the 2026 offering, about $901,000 each
$1.83MSold in the 2023 offering, against a $4.2M announced pre-seed

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Summer 2021 Y Combinator batch S21 Not disclosed Y Combinator YC data
Feb 2023 Equity offering, first sale Feb 6, 2023 $1,829,000 sold of $3,000,000 offered 18 investors, not named in the filing Form D
Apr 2023 Pre-seed, as announced $4.2M BlueYard Capital lead; Y Combinator, Amino Collective, Civilization Ventures, Recode Health Ventures, ZAKA; angels including Florian Schuster and Jason C. Foster Company release
By Jun 2025 Cumulative, as stated by the company More than $13M Recode Ventures, BlueYard Capital, Kaya VC, Backed VC, Y Combinator, ZAKA VC, Onsight Company release
2024 list Cumulative, as reported Around $10M Most recent round led by Recode Ventures Forbes
Aug to Sep 2026 Equity offering, first sale Aug 17, 2026 $13,518,941 sold of $15,000,000 offered 15 investors, not named in the filing Form D

What the filings show

Sensible Biotechnologies, Inc. · Form D · filed Sep 2, 2026

First sale
Aug 17, 2026
Offered
$15,000,000 equity
Sold
$13,518,941 · $1,481,059 remaining
Investors
15 · average about $901,000
Exemption
Rule 506(b)
To officers
$200,000 of proceeds stated as payments to executive officers, directors or promoters
Related persons
Miroslav Gasparek (executive officer, director); Marian Kupculak (executive officer, director); Joel Schoppig (director); Vishal Gulati (director)
Issuer address
Oxford, Oxfordshire · incorporated in Delaware, 2021
Filing
SEC EDGAR, CIK 0001964363

Sensible Biotechnologies, Inc. · Form D · filed Feb 21, 2023

First sale
Feb 6, 2023
Offered
$3,000,000 equity
Sold
$1,829,000 · $1,171,000 remaining
Investors
18 · average about $101,600
Exemption
Rule 506(b)
To officers
$100,000 of proceeds stated as payments to executive officers, directors or promoters
Related persons
Miroslav Gasparek (executive officer, director); Marian Kupculak (executive officer, director)
Issuer address
Claymont, Delaware
Filing
SEC EDGAR, CIK 0001964363

Reading the filings

  1. The 2026 round is institutional, the 2023 round was not.$13,518,941 across 15 investors is about $901,000 each. The 2023 offering averaged about $101,600 across 18 investors. The first is the shape of a venture round, the second the shape of an angel and micro fund round.
  2. The announced pre-seed is larger than any filing supports.The April 2023 release put the pre-seed at $4.2 million. The Form D filed on February 21, 2023 reported $1,829,000 sold out of a $3,000,000 offering, and no amendment ever followed. Even a fully subscribed offering would have left $1.2 million unaccounted for. Money raised outside Regulation D, for instance from investors outside the United States or under Section 4(a)(2), never reaches a Form D, so the gap is a reporting gap rather than proof the announcement was wrong.
  3. Three and a half years with nothing on EDGAR.Between February 2023 and September 2026 the company filed no exempt offering notice, yet in June 2025 it stated it had raised more than $13M and Forbes put the founders at around $10 million. Whatever closed that gap did not travel through a reported Regulation D offering in the United States.
  4. The board grew with the money.The 2023 notice lists only the two founders as related persons. The 2026 notice adds Joel Schoppig and Vishal Gulati as directors. Outside directors arriving at the same moment as a $13.5 million first sale is the usual signature of priced institutional terms.
  5. The 2026 offering is not closed.$1,481,059 of the $15,000,000 was still unsold at the filing date. An amendment, if one comes, will say whether the rest filled.
  6. The operating company had real money before the round.The Slovak subsidiary held EUR 940,337 in bank accounts at December 31, 2025, against EUR 126,875 a year earlier, and carried EUR 719,036 of short term deferred income into 2026. That balance predates the August 2026 first sale by eight months.

Commercial signals

Signal Detail Source type
Operating revenue Sensible Biotechnologies s.r.o. reported revenue from services of EUR 1,064,658 for the year to Dec 31, 2025 and EUR 1,043,627 for 2024, with profit after tax of EUR 31,501 and EUR 35,580. Public record
Payroll Personnel costs of EUR 396,945 in 2025, up from EUR 251,074, at the Slovak subsidiary. Public record
Balance sheet Slovak subsidiary equity of EUR 386,920 at Dec 31, 2025, including EUR 403,368 of capital contributions from the parent, up EUR 100,000 in the year. Public record
UK entity SENSIBLE BIOTECHNOLOGIES LIMITED files micro company accounts and has no registered charges. Registered office is an accountancy address in Altrincham, Cheshire. Public record
Partners Sartorius Stedim Biotech memorandum of understanding, July 2025; NVIDIA computing initiative, June 2025; Ginkgo Bioworks co-development, 2023. Company-stated
Customers 10 letters of intent claimed in 2023. None named since. Company-stated
Clinical evidence No registered trials, no FDA submissions, and no peer reviewed publication on the platform found. Not found

What to watch

  • An amended Form D for the 2026 offering, which would settle whether the last $1,481,059 sold.
  • The Slovak accounts for the year to December 31, 2026, the first set to reflect the new capital.
  • The first UK accounts that stop qualifying as micro company accounts.
  • A named customer or a signed supply agreement in place of letters of intent.
  • Whether clinical grade material arrives on the 2026 timeline stated with Sartorius.

The Sensible Biotechnologies story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Catena Biosciences: Shared investor: Blueyard Capital. A UC Berkeley spinout that uses an engineered tyrosinase to weld two proteins together through their native amino acids, now aimed at antibody drug conjugates carrying
  • MediSearch: Shared investor: Kaya Vc. A search engine that answers medical questions from published sources, built by two founders and backed by Y Combinator
  • Kernal Biologics: Shared investor: Civilization Ventures. A Boston company designing messenger RNA that switches on only inside the cells it is aimed at, now building an in vivo CAR T therapy on that idea
  • Excepgen: Shared investor: Zaka Vc. A San Francisco biotech that started by engineering human cells to make hard to express proteins for drug discovery, and has since turned to a different problem

Sources

  1. Public recordForm D, Sensible Biotechnologies, Inc., accession 0001964363-26-000003SEC · Sep 2, 2026
  2. Public recordForm D, Sensible Biotechnologies, Inc., accession 0001964363-23-000001SEC · Feb 21, 2023
  3. Public recordEDGAR company filing index, CIK 0001964363SEC · accessed Sep 22, 2026
  4. Public recordFinancial statements of Sensible Biotechnologies s.r.o., 2025 and 2024Slovak Register of Financial Statements · filed Jun 26, 2026
  5. Public recordExtract for Sensible Biotechnologies s.r.o., section Sro, file 157306/BSlovak Business Register · accessed Sep 23, 2026
  6. Public recordSENSIBLE BIOTECHNOLOGIES LIMITED, company 14628427, accounts, officers and chargesCompanies House · accessed Sep 22, 2026
  7. IndependentSensible Biotechnologies company profile, 30 Under 30 EuropeForbes · 2024 list
  8. IndependentSensible Biotechnologies announced it raised $13.5 Million in an initial filingFundz · Sep 2, 2026
  9. IndependentSensible Biotechnologies funding record, one round, EUR 3.8MTech.eu funding database · accessed Sep 22, 2026
  10. CompanySensible Biotechnologies Raises $4.2mn in a Pre-Seed Financing RoundPR Newswire · Apr 6, 2023
  11. CompanySensible Biotechnologies Teams Up With NVIDIA, with cumulative funding statementsensible.bio · Jun 12, 2025
  12. PartnerSartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale UpSartorius · Jul 9, 2025

Compiled from SEC, Companies House, Slovak Business Register and Slovak Register of Financial Statements records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Sensible Biotechnologies. This page is not an offer to sell or a recommendation to buy any security.